The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …

The treatment of cancer patients has dramatically changed over the past decades with the
advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and …

Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—
the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells …

A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as
highly effective treatments for solid tumours. ADCs conjugate conventional …

Approximately half of breast cancers (BCs), historically categorized as human epidermal
growth factor receptor 2 (HER2)-negative, have low expression of HER2 defined as an …

Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is
composed of three main components: a monoclonal antibody (mAB) targeting a specific …

Background Human epidermal growth factor receptor 2 (HER2)-low expression in breast
cancer has been recently identified as a new therapeutic target. However, it is unclear if …

Background Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor
receptor 3 (HER3)-directed antibody–drug conjugate composed of a fully human anti-HER3 …